Edition:
United States

Mirati Therapeutics Inc (MRTX.PH)

MRTX.PH on Philadelphia Stock Exchange

5.12USD
22 Mar 2017
Change (% chg)

-- (--)
Prev Close
$5.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
674
52-wk High
$24.20
52-wk Low
$4.44

MRTX.PH

Chart for MRTX.PH

About

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $128.44
Shares Outstanding(Mil.): 24.94
Dividend: --
Yield (%): --

Financials

  MRTX.PH Industry Sector
P/E (TTM): -- 48.09 29.63
EPS (TTM): -4.20 -- --
ROI: -99.74 -2.54 13.01
ROE: -99.85 5.17 14.16

BRIEF-Broadfin Capital LLC reports 6.90 pct passive stake in Mirati Therapeutics Inc as of Jan 6, 2017

* Broadfin Capital LLC reports 6.90 percent passive stake in Mirati Therapeutics Inc as of January 6, 2017 - Sec Filing Source text (http://bit.ly/2ibJ1uN) Further company coverage:

Jan 09 2017

BRIEF-Mirati Therapeutics announces pricing of public offering of common stock

* Pricing of underwritten public offering of 4.4 million shares of common stock at a price to public of $5.60 per share

Jan 06 2017

BRIEF-Mirati Therapeutics announces pricing of public offering of common stock

* Mirati Therapeutics announces pricing of public offering of common stock

Jan 06 2017

BRIEF-Mirati Therapeutics reports Q3 loss per share $0.97

* Mirati Therapeutics reports financial results and provides business update for the third quarter 2016

Nov 03 2016

More From Around the Web

Earnings vs. Estimates